Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab
https://doi.org/10.14412/1995-4484-2013-1514
For citations:
Muravyev Yu.V., Gridina G.I., Karateev D.E. Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab. Rheumatology Science and Practice. 2013;51(3):354-356. (In Russ.) https://doi.org/10.14412/1995-4484-2013-1514
Views:
704
Email this article 